Literature DB >> 17101762

Laboratory research in homeopathy: con.

John R Moffett1, Peethambaran Arun, M A A Namboodiri.   

Abstract

Alternative medical approaches to human diseases such as cancer are becoming increasingly popular, but reports on their success rates have been highly variable. Homeopathy is an alternative medical practice often applied to less critical human diseases but one that has also been applied sporadically to the treatment of cancer. Animal studies on the use of homeopathy to treat experimental cancer are few and the evidence provided to date is far from conclusive. The debate presented here concerns the utility of animal studies on cancer treatment with homeopathic preparations. As part of a Point-Counterpoint feature, this review and its companion piece in this issue by Khuda-Bukhsh (Integr Cancer Ther. 2006;5:320-332) are composed of a thesis section, a response section in reaction to the companion thesis, and a rebuttal section to address issues raised in the companion response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101762     DOI: 10.1177/1534735406294795

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  2 in total

1.  Ultra-diluted Folliculinum 6 cH impairs ovine oocyte viability and maturation after in vitro culture.

Authors:  Kayse Najara Matos Damasceno; Naiza Arcângela Ribeiro de Sá; Gildas Mbemya Tetaping; Victor Macedo Paes; Laritza Ferreira de Lima; Antônio Carlos Duenhas Monreal; Francisca Geovânia Canafistula de Sousa; Bênner Geraldo Alves; José Ricardo de Figueiredo; Valdevane Rocha Araújo
Journal:  Anim Reprod       Date:  2020-06-18       Impact factor: 1.807

2.  Modulation of Signal Proteins: A Plausible Mechanism to Explain How a Potentized Drug Secale Cor 30C Diluted beyond Avogadro's Limit Combats Skin Papilloma in Mice.

Authors:  Anisur Rahman Khuda-Bukhsh; Soumya Sundar Bhattacharyya; Saili Paul; Suman Dutta; Naoual Boujedaini; Philippe Belon
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-18       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.